We are live on ! Find out more
ORMP icon

Oramed Pharmaceuticals
ORMP

71 hedge funds and large institutions have $25.5M invested in Oramed Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 23 increasing their positions, 23 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

508% more call options, than puts

Call options by funds: $3.68M | Put options by funds: $605K

0% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 23

6.98% less ownership

Funds ownership: 17.12% → 10.15% (-7%)

14% less capital invested

Capital invested by funds: $29.6M → $25.5M (-$4.11M)

19% less funds holding

Funds holding: 88 → 71 (-17)

79% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 19

Holders
71
Holders Change
-17
Holders Change %
-19.32%
% of All Funds
1.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
23
Reduced
23
Closed
19
Calls
$3.68M
Puts
$605K
Net Calls
+$3.08M
Net Calls Change
+$2.45M

Top Buyers

Rank Fund Capital Flow
1
Walleye Capital
Walleye Capital
New York
+$635K
2
Man Group
Man Group
United Kingdom
+$574K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$524K
4
Wells Fargo
Wells Fargo
California
+$435K
5
JSMC
Jess S. Morgan & Co
California
+$414K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$4.39M
2
Two Sigma Investments
Two Sigma Investments
New York
-$3.86M
3
Two Sigma Advisers
Two Sigma Advisers
New York
-$2.84M
4
Renaissance Technologies
Renaissance Technologies
New York
-$1.65M
5
E
Ergoteles
New York
-$1.62M
Name Holding Trade Value Shares
Change 		Change in
Stake
BCM
51
Bourgeon Capital Management
Connecticut
$36K – – –
HNB
52
Huntington National Bank
Ohio
$33K – – –
Rockefeller Capital Management
53
Rockefeller Capital Management
New York
$25K – – –
CAM
54
Close Asset Management
United Kingdom
$21K +$8.9K +1,100 +52%
ME
55
McIlrath & Eck
Washington
$19K – – –
IA
56
IFP Advisors
Florida
$14K – – –
CG
57
Cutler Group
California
$11K +$9.82K +1,213 +243%
Northwestern Mutual Wealth Management
58
Northwestern Mutual Wealth Management
Wisconsin
$10K +$12.7K +1,575 New
CHC
59
City Holding Co
West Virginia
$7K – – –
SPIA
60
Steward Partners Investment Advisory
New York
$6K -$8.09K -1,000 -50%
CFGS
61
Concourse Financial Group Securities
Alabama
$6K – – –
NFSG
62
Newbridge Financial Services Group
Florida
$4K – – –
CCM
63
Covington Capital Management
California
$2K – – –
TSWM
64
Tyler-Stone Wealth Management
Ohio
$2K – – –
AWM
65
Activest Wealth Management
Florida
$2K +$2.87K +355 New
TRCT
66
Tower Research Capital (TRC)
New York
$1K -$13.3K -1,647 -89%
GRP
67
Global Retirement Partners
California
$1K – – –
TWA
68
TCI Wealth Advisors
Arizona
$1K – – –
TF
69
TimeScale Financial
Massachusetts
$1K – – –
BNP Paribas Financial Markets
70
BNP Paribas Financial Markets
France
$836 -$552K -68,221 -100%
Renaissance Technologies
71
Renaissance Technologies
New York
– -$1.65M -359,697 Closed
Bank of Montreal
72
Bank of Montreal
Ontario, Canada
– -$1.35K -249,200 Closed
Squarepoint
73
Squarepoint
New York
– -$532K -116,065 Closed
OC
74
Oppenheimer & Co
New York
– -$229K -50,000 Closed
RPC
75
Rossmore Private Capital
Connecticut
– -$186K -40,661 Closed
1 2
3
4

ORMP Hedge Fund Activity: Q3 2022 in Review

71 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q3 2022, worth a combined $25.5M — down 14% from $29.6M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of ORMP and 4 opened new positions — a net loss of 15 holders — while 23 trimmed existing stakes and 23 added.

The largest buyer was Walleye Capital, opening a new position worth an estimated $635K. The largest seller was Citadel Advisors, cutting an estimated $4.39M.

  • 71 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q3 2022, down from 88 in Q2 2022.
  • Funds reported $25.5M of Oramed Pharmaceuticals stock for Q3 2022, down 14% quarter-over-quarter.
  • 4 funds opened new Oramed Pharmaceuticals positions in Q3 2022 and 19 closed out, a net change of -15 holders.
  • The largest Oramed Pharmaceuticals buyer in Q3 2022 was Walleye Capital, an estimated $635K added.
  • The largest Oramed Pharmaceuticals seller in Q3 2022 was Citadel Advisors, an estimated $4.39M sold.

Based on aggregated 13F filings for Q3 2022.